Jul 17, 2007|
Pharma: Europe and ROW focus
The high level of competition witnessed in the US generics market has propelled generic companies both in India and globally to geographically diversify in a bid to de-risk their revenue profile and sustain overall profitability. And while Europe has been the next best choice, the emerging markets of Latin America, Africa, CIS and central and Eastern Europe have also come on the radar of domestic pharma companies. In this article, we shall take a look at the potential of these markets and the challenges going forward.
Europe is a heterogeneous market as compared to the US with each country having different market characteristics and regulations. Besides this, while the generics penetration in the UK and Germany is high, the same is relatively lesser in markets such as France, Italy and Spain, indicating the potential for generics to gain traction going forward. Akin to the US, the governments of the European nations are also under pressure to reduce healthcare costs given the rise in the aged population and thereby the increased spending on pharmaceuticals. Also, branded generics can be launched in some of these markets, as a result of which companies here can earn higher profits. Thus, domestic pharma companies having been making increasing strides in the European markets by acquiring companies with a strong product pipeline and an established marketing network. The rationale for making acquisitions is to obviate the need to establish a presence in Europe right from scratch.
Why the emerging markets?
Domestic pharma companies have evinced a lot of interest in the emerging markets of late as these markets have been growing much faster than the US and Europe, posting double-digit growth rates. Since these markets are not as regulated as those in the US and Europe, generics here can be branded, consequently enabling companies to earn higher margins. The disease profile in these countries is also shifting towards the chronic therapy segment and in the African continent, organisations such as the WHO and the PEPFAR are playing an important role in funding healthcare costs (especially for diseases such as AIDS, the prevalence of which is very high in Africa). Hence, given the potential, domestic pharma companies are setting shop in these countries to boost revenues and profitability and partially offset the pricing pressure witnessed not only in the US market but also in some of the western European countries.
The challenges are...
While Europe is increasingly becoming a focus area for domestic pharma companies, there has been a perceptible shift in the dynamics of the western European markets. For instance, the UK has been facing severe pricing pressure and regulatory changes in France and Germany have taken its toll on the performance of Indian companies present in these markets. To put things into perspective, while Germany initially was a branded generics market, the new set of regulatory changes in the German healthcare system are expected to commoditise generics going forward. This means that pricing pressure is likely to be persistent in this market as well. While the efforts of the government to increase the use of generics will bolster volumes, efforts to control costs is likely to escalate into pricing pressure going forward.
In the emerging markets, competition is likely to intensify as more and more companies establish a presence in these countries. Despite this, the growth in revenues and margins are likely to be on the higher side as compared to the US and Western Europe. This is because these emerging markets have been growing at a much faster pace led by a higher per capita pharmaceutical expenditure and an increasing utilisation of generic drugs.
To sum up...
Presence across geographies has been gaining momentum across global generic companies. Besides domestic companies such as Ranbaxy, Dr.Reddy's and Sun Pharma, global generic companies such as Teva and Mylan have also been focusing on establishing a global footprint and hence have been active on the acquisition front. Given the high barriers to entry in terms of product introduction and a strong marketing network, at the end of the day those pharma companies, which have a wider geographical reach, will have the upper edge over their peers in the longer term.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 16, 2017
Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 10, 2017
Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407